Isoegomaketone from (L.) Britt Stimulates MAPK/ERK Pathway in Human Keratinocyte to Promote Skin Wound Healing.

Ye-Ram Kim, Bomi Nam, Ah-Reum Han, Jin-Baek Kim, Chang Hyun Jin
Author Information
  1. Ye-Ram Kim: Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup, Jeollabuk-do 56212, Republic of Korea. ORCID
  2. Bomi Nam: Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup, Jeollabuk-do 56212, Republic of Korea.
  3. Ah-Reum Han: Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup, Jeollabuk-do 56212, Republic of Korea. ORCID
  4. Jin-Baek Kim: Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup, Jeollabuk-do 56212, Republic of Korea.
  5. Chang Hyun Jin: Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup, Jeollabuk-do 56212, Republic of Korea. ORCID

Abstract

Skin wound healing is essential for recovery from injury, and delayed or impaired wound healing is a severe therapeutic challenge. Keratinocytes, a major component of the epidermis, play crucial roles in reepithelialization during wound healing including cell proliferation. Recent studies have shown that compounds from natural products have candidates for healing skin injury. Isoegomaketone (IK), isolated from leaves of var. (Lamiaceae), has various bioactivities. However, the effect of IK on cutaneous wound healing processes has not been studied yet. In this study, we demonstrated that IK exhibits therapeutic wound healing effects using the Human keratinocyte cell line HaCaT. Notably, IK promoted cell proliferation and migration in a dose-dependent manner in vitro, and treatment with 10 M IK upregulated these processes by approximately 1.5-fold after 24 h compared with the control. IK induced the activation of the MAPK/ERK pathway and cell cycle progression to the S and G2/M phases. Thus, this study demonstrates IK as a potential candidate to upregulate wound healing that may provide therapeutic benefits to patients with delayed wound healing.

References

  1. Molecules. 2017 Jul 19;22(7): [PMID: 28753954]
  2. Evid Based Complement Alternat Med. 2018 Jul 26;2018:4580627 [PMID: 30147732]
  3. Adv Wound Care (New Rochelle). 2014 Jan 1;3(1):71-79 [PMID: 24761347]
  4. Indian J Plast Surg. 2012 May;45(2):418-24 [PMID: 23162243]
  5. Int J Inflam. 2015;2015:316235 [PMID: 26356299]
  6. Materials (Basel). 2017 Jul 22;10(7): [PMID: 28773202]
  7. J Am Acad Dermatol. 2010 Nov;63(5):866-81 [PMID: 20576319]
  8. Radiother Oncol. 1986 Aug;6(4):285-92 [PMID: 3095892]
  9. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3826-31 [PMID: 22355113]
  10. J Agric Food Chem. 2010 Jan 27;58(2):860-7 [PMID: 20030328]
  11. Cell Res. 2002 Mar;12(1):9-18 [PMID: 11942415]
  12. Exp Mol Med. 2010 Apr 30;42(4):270-9 [PMID: 20177149]
  13. J Invest Dermatol. 2018 Oct;138(10):2253-2263 [PMID: 29605672]
  14. J Immunol. 2012 Sep 15;189(6):3231-41 [PMID: 22904306]
  15. Dermatol Clin. 1993 Oct;11(4):749-57 [PMID: 8222358]
  16. Mol Biol Cell. 2012 Sep;23(18):3722-30 [PMID: 22833568]
  17. Molecules. 2018 Dec 28;24(1): [PMID: 30597896]
  18. J Clin Endocrinol Metab. 2000 Jul;85(7):2576-83 [PMID: 10902811]
  19. Biochim Biophys Acta. 2007 Aug;1773(8):1299-310 [PMID: 17188374]
  20. Anat Cell Biol. 2019 Sep;52(3):324-332 [PMID: 31598362]
  21. J Invest Dermatol. 2007 May;127(5):998-1008 [PMID: 17435785]
  22. Sci Rep. 2018 Sep 26;8(1):14398 [PMID: 30258088]
  23. Eur Surg Res. 2017;58(1-2):81-94 [PMID: 27974711]
  24. Nutr Res Pract. 2015 Feb;9(1):11-6 [PMID: 25671062]
  25. Biosci Biotechnol Biochem. 2001 Jul;65(7):1673-5 [PMID: 11515557]
  26. Arch Pharm Res. 2011 Aug;34(8):1277-82 [PMID: 21910048]
  27. Cell Physiol Biochem. 2018;49(6):2229-2239 [PMID: 30257250]
  28. Antioxidants (Basel). 2019 Feb 06;8(2): [PMID: 30736314]
  29. Molecules. 2017 Feb 17;22(2): [PMID: 28218690]
  30. J Dent Res. 2010 Mar;89(3):219-29 [PMID: 20139336]
  31. Int J Inflam. 2019 Jun 2;2019:3706315 [PMID: 31275545]
  32. Int J Mol Sci. 2020 Apr 30;21(9): [PMID: 32366052]
  33. Pharmaceutics. 2020 Aug 05;12(8): [PMID: 32764269]
  34. BMB Rep. 2018 Apr;51(4):188-193 [PMID: 29335070]
  35. Evid Based Complement Alternat Med. 2019 Sep 22;2019:2684108 [PMID: 31662773]
  36. Adv Wound Care (New Rochelle). 2014 Jul 1;3(7):445-464 [PMID: 25032064]
  37. Pharmacogn Rev. 2012 Jan;6(11):1-5 [PMID: 22654398]
  38. J Biol Chem. 2004 Jul 30;279(31):32633-42 [PMID: 15145954]
  39. Evid Based Complement Alternat Med. 2018 Feb 19;2018:3142073 [PMID: 29670658]
  40. Front Pharmacol. 2020 Feb 28;11:153 [PMID: 32184728]
  41. ISRN Obes. 2014 Feb 20;2014:638936 [PMID: 24701367]

Word Cloud

Created with Highcharts 10.0.0healingwoundIKcelltherapeuticSkininjurydelayedproliferationIsoegomaketoneprocessesstudyMAPK/ERKessentialrecoveryimpairedseverechallengeKeratinocytesmajorcomponentepidermisplaycrucialrolesreepithelializationincludingRecentstudiesshowncompoundsnaturalproductscandidatesskinisolatedleavesvarLamiaceaevariousbioactivitiesHowevereffectcutaneousstudiedyetdemonstratedexhibitseffectsusinghumankeratinocytelineHaCaTNotablypromotedmigrationdose-dependentmannervitrotreatment10 Mupregulatedapproximately15-fold24 hcomparedcontrolinducedactivationpathwaycycleprogressionSG2/MphasesThusdemonstratespotentialcandidateupregulatemayprovidebenefitspatientsLBrittStimulatesPathwayHumanKeratinocytePromoteWoundHealing

Similar Articles

Cited By (8)